Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease [Yahoo! Finance]
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Voyager Therapeutics, Inc. (NASDAQ: VYGR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.